133366-32-2 Usage
Bicyclic structure
The compound has a two-ring structure, with the carbon atoms arranged in a closed loop.
Nitrogen atom
The compound contains one nitrogen atom, which is an essential component of its structure and reactivity.
Carbonitrile group
The compound has a carbonitrile group (C≡N), a functional group consisting of a triple-bonded carbon atom and a nitrogen atom.
Endo isomer
The nitrogen atom is located within the ring structure, making it an endo isomer.
Organic synthesis applications
The compound has potential applications in organic synthesis due to its unique structure and reactivity.
Pharmaceutical research
The compound may be used in pharmaceutical research for the development of new drugs, as its properties and potential uses make it an important compound for further study.
Importance in organic chemistry
The compound's structure and reactivity make it a valuable subject for research and development in the field of organic chemistry.
Drug discovery potential
The compound's unique properties and potential uses contribute to its significance in the field of drug discovery.
Check Digit Verification of cas no
The CAS Registry Mumber 133366-32-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,3,3,6 and 6 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 133366-32:
(8*1)+(7*3)+(6*3)+(5*3)+(4*6)+(3*6)+(2*3)+(1*2)=112
112 % 10 = 2
So 133366-32-2 is a valid CAS Registry Number.
133366-32-2Relevant articles and documents
Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands
Jenkins,Wadsworth,Bromidge,Orlek,Wyman,Riley,Hawkins
, p. 2392 - 2406 (2007/10/02)
The effect of variation of the 1-azabicyclic substituent on the novel 1,2,3-triazol-4-yl-, 1,2,4-triazol-1-yl-, tetrazol-5-yl-, and tetrazol-2-yl- based muscarinic receptor ligands has been studied, and the exo- azabicyclic[2.2.1]hept-3-yl substituent was found to give the most potent and efficacious compounds. In addition, variation of the second substituent on 1,2,4-triazol-1-yl- and tetrazol-2-yl-based muscarinic receptor ligands has yielded a series of novel compounds with high potencies and efficacies, ranging from full agonists to antagonists. Small lipophilic electron withdrawing substituents give potent but low efficacy compounds, while small polar electron donating substituents give potent and efficacious compounds. The activity of these compounds is described in terms of a model of the receptor involving lipophilic and hydrogen bonding interactions. These compounds provide muscarinic ligands with high potency and a range of efficacies suitable for testing as candidate drugs in the treatment of Alzheimer's disease.
